Clinical trials: Endocrine Therapy
Ovarian Cancer
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
This multicenter, open-label, prospective cohort clinical study enrolled 70 patients with late-stage ER（+）platinum-sensitive recurrent ovarian cancer who had achieved CR/PR after first-line PARP inhibitor maintenance therapy.
- Trial name
- NCT07000344
- Testing
- Cohort 1 (triple-drug group), Cohort 2 (dual-drug group)
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking Union Medical College Hospital
Diabetic Foot Ulcers, Diabetic Wound
The Effect of Platelet-Rich Plasma-Fibrin Glue in Combination With Vitamin E and C for Treatment of Non-healing Diabetic Foot Ulcers
The aim of this study is to evaluates the chance of non-healing Diabetic Foot Ulcers repair by reducing oxidative stress caused by diabetes by taking vitamin E and C supplements along with the use of Platelet-Rich Plasma-Fibrin…
- Trial name
- NCT04315909
- Testing
- PRP-Fibrin Glue, Vitamin E and C
- Where
- Iran
- Volunteers
- 24 people
- Sponsor
- Mashhad University of Medical Sciences
Pancreatic Cancer
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with radiation therapy and/or surgery may kill more tumor cells.
- Trial name
- NCT00003332
- Testing
- cisplatin, gemcitabine hydrochloride, surgical procedure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- NYU Langone Health
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of…
- Trial name
- NCT00948493
- Testing
- Buccal insulin spray
- Sponsor
- Generex Biotechnology Corp.
Growth Hormone Deficiency (GHD)
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive…
- Trial name
- NCT06948214
- Testing
- LUM-201
- Where
- 55 sites in United States, Argentina and 6 more
- Volunteers
- 150 people
- Sponsor
- Lumos Pharma
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Hormone Deficiency
Hormone Treatment in Growth Hormone and Testosterone Deficient Patients
Growth hormone and gonadotropin deficiency after brain injury (traumatic brain injury, ischemic stroke, subarachnoidal hemorrhage): the effects of hormone replacement on cognition, quality of life and body composition Randomized…
- Trial name
- NCT01397500
- Testing
- Genotropin, Testosterone undecannoate
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Pancreatic Cancer
XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) in combination with chemotherapy as Adjuvant Therapy in pancreatic cancer…
- Trial name
- NCT07114666
- Testing
- XH001, Chemotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking Union Medical College Hospital
Acromegaly
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
- Trial name
- NCT00151437
- Testing
- Pegvisomant treatment, Medical History, demographics, Sign and symptoms: questionnaire
- Where
- 5 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Pfizer
Diabetic Neuropathies
Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy
The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.
- Trial name
- NCT00229437
- Testing
- TAK-128
- Where
- 48 sites in United States, Canada
- Volunteers
- 343 people
- Sponsor
- Takeda
Ovarian Carcinoma
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
Preclinical studies showed that metronomic chemotherapy can induce tumor regression secondary to apoptosis of the tumor blood vessels. This effect was increased by combining metronomic chemotherapy with anti-angiogenic drugs.
- Trial name
- NCT01175772
- Testing
- Cytophosphan, Celecoxib, Methotrexate
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- HaEmek Medical Center, Israel
Pancreatic Cancer
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
- Trial name
- PANC (NCT03322995)
- Testing
- First-line Chemotherapy, Second-line Chemotherapy, Chemoradiation
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Medical College of Wisconsin
Pancreatic Cancer
A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy
The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of pancreatic cancer metastasis in subjects receiving standard therapy.
- Trial name
- NCT00810953
- Testing
- Pentamidine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Oncozyme Pharma Inc.
Diabetes, Diabetes Mellitus, Type 2
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily
This trial is conducted globally. The aim of the trial is to compare efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) + insulin aspart (IAsp) once daily (OD) versus basal bolus with insulin degludec (IDeg)…
- Trial name
- BOOST® (NCT01814137)
- Testing
- insulin degludec/insulin aspart, insulin degludec, insulin aspart
- Where
- 40 sites in United States, Algeria and 3 more
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Colorectal Cancer, Pancreatic Cancer
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
This clinical trial will utilize a neoantigen nanovaccine constructed from the bacterial membranes of an engineered Lactococcus lactis strain (FOLactis).
- Trial name
- NCT07353645
- Testing
- KRAS Neoantigen Nanovaccine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Breast Cancer, Estrogen Receptor Positive Tumor
Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10% CD8+ T cells in the tumor).
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, Menopause, Hormone Antagonist
- Trial name
- ULTIMATE (NCT02997995)
- Testing
- Immune-attractant, Durvalumab, Biopsy
- Where
- 29 sites in France, Spain and 1 more
- Volunteers
- 61 people
- Sponsor
- UNICANCER
Gynecologic Cancer, Cancer Metastatic
Study of AK112 in the Treatment of Advanced Gynecological Tumors
A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.
- Conditions
- Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm
- Trial name
- NCT04870177
- Testing
- AK112
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Akeso
Myocardial Infarction, Coronary Artery Diseases
Physical and Chemical Study of Atherosclerosis Mechanisms
Study the mechanisms of atherosclerosis based on a comparative study of physical and chemical properties of lipid tissues at various localization with subsequent development of concept of treatment and prevention.
- Conditions
- Myocardial Infarction, Coronary Artery Diseases, Diabetes Mellitus, Type 2, Atherosclerosis of Femoral Artery
- Trial name
- PCSAM (NCT01700075)
- Testing
- Conventional treatment, Weight loss treatment
- Where
- Kazakhstan
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Nazarbayev University
Breast Cancer
Prospective Observational Study of Antitumor Activity Correlation Between Hormonal Therapy and Expression miRNA100
Mono-centric, observational, prospective study, designed for pts with diagnosis of hormone-positive breast cancer to evaluate the correlation between the response to hormonal treatment indicated by the reduction of the level of…
- Trial name
- BC-P1-2013 (NCT02950207)
- Testing
- miRNA
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Cancer, Overall Survival
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree…
- Trial name
- METRICS (NCT02201381)
- Testing
- Metabolic treatment
- Where
- United Kingdom
- Sponsor
- Health Clinics Limited